Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service sleep apnea & airway implants cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (12 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 0 | 27 | 47% |
| 2020 | 0 | 14 | 49% |
| 2021 | 2 | 18 | 51% |
| 2022 | 5 | 163 | 53% |
| 2023 | 6 | 241 | 56% |
| 2024 | 8 | 263 | 58% |
| 2025 from claims | – | 196 159–230 | 59% |
| 2026 forecast | – | 216 169–271 | 59% |
| 2027 forecast | – | 234 173–309 | 59% |
| 2028 forecast | – | 254 180–350 | 60% |
| 2029 forecast | – | 275 187–394 | 60% |
| 2030 forecast | – | 298 195–442 | 61% |
Hypoglossal nerve stimulation and upper airway procedures. Professional codes (what the surgeon bills): CPT 64582, 64583, 64584, 42145, 41530.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Pennsylvania; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 2 | 146+38%/yr | +38%/yr | 0.1 | 19% | 160 in 2030+1.2%/yr |
| Massachusetts | 2 | 127+63%/yr | +63%/yr | 0.1 | 0% | 110 in 2030−2.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Sinus surgery & balloon dilation | 51 | 5,134−4.5%/yr | −4.5%/yr | 3.81.1× | 58% | 5,170 in 2030+0.1%/yr |
| Ear tubes & middle ear surgery | 8 | 528−9.9%/yr | −9.9%/yr | 0.42.0× | 47% | 490 in 2030−1.1%/yr |
| Cochlear implants | 4 | 159+3.5%/yr | +3.5%/yr | 0.11.4× | 0% | 150 in 2030−1.3%/yr |
Sleep apnea & airway implants in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
Itamar Medical leads with 52% of company spending on these surgeons in 2025, −18 pts on 2024.
In 2025, 9 companies reported engagement with Pennsylvania’s surgeons worth $632K in consulting, speaking, meals and travel tied to these products, about $79K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 18 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.